A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (“LDD™”) and related accessories. The LAL is a premium intraocular lens (“IOL”) made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (“UV”) light patterns generated by the LDD.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 134M | 134M | 140M | 89M | 49M | - |
| Net Income | -39M | -39M | -27M | -49M | -67M | -49M |
| EPS | $-0.95 | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| Free Cash Flow | -19M | -19M | -22M | -46M | -61M | -47M |
| ROIC | -14.9% | -14.1% | -9.8% | -30.3% | -74.3% | -27.4% |
| Gross Margin | 76.6% | 76.6% | 70.7% | 60.4% | 43.5% | - |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -48M | -48M | -37M | -50M | -63M | -53M |
| Operating Margin | -35.8% | -35.8% | -26.3% | -56.2% | -129.2% | - |
| ROE | -14.1% | -14.0% | -9.8% | -30.3% | -74.3% | -35.2% |
| Shares Outstanding | 41M | 41M | 39M | 34M | 28M | 34M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 15M | N/A | 49M | 89M | 140M | 134M | 134M |
| Gross Margin | 11.6% | N/A | 43.5% | 60.4% | 70.7% | 76.6% | 76.6% |
| R&D | 22M | 24M | 26M | 29M | 34M | 39M | 39M |
| SG&A | 15M | 33M | 59M | 75M | 101M | 113M | 113M |
| EBIT | -35M | -53M | -63M | -50M | -37M | -48M | -48M |
| Op. Margin | -241.3% | N/A | -129.2% | -56.2% | -26.3% | -35.8% | -35.8% |
| Net Income | 3.4M | -49M | -67M | -49M | -27M | -39M | -39M |
| Net Margin | 22.9% | N/A | -136.2% | -54.6% | -19.6% | -29.0% | -29.0% |
| Non-Recurring | 7K | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -35.1% | -27.4% | -74.3% | -30.3% | -9.8% | -14.1% | -14.9% |
| ROE | N/A | -35.2% | -74.3% | -30.3% | -9.8% | -14.0% | -14.1% |
| ROA | 3.3% | -25.3% | -44.5% | -26.6% | -8.6% | -12.4% | -12.5% |
| Cash Flow | |||||||
| Op. Cash Flow | -35M | -45M | -59M | -42M | -17M | -16M | -16M |
| Free Cash Flow | -38M | -47M | -61M | -46M | -22M | -19M | -19M |
| Owner Earnings | -43M | -56M | -74M | -61M | -45M | -50M | -50M |
| CapEx | 2.5M | 1.9M | 2.4M | 4.8M | 5.4M | 3.8M | 3.8M |
| Maint. CapEx | 3.9M | 4.0M | 3.9M | 4.1M | 3.6M | 3.3M | 3.3M |
| Growth CapEx | 0 | 0 | 0 | 736K | 1.9M | 564K | 564K |
| D&A | 3.9M | 4.0M | 3.9M | 4.1M | 3.6M | 3.3M | 3.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.2M | 7.6M | 11M | 16M | 25M | 32M | 32M |
| Debt Repayment | 687K | 132K | 145K | 2.2M | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -45M | -120M | -106M | -127M | -237M | -228M | -20M |
| Cash & Equiv. | 14M | 24M | 12M | 9.7M | 17M | 20M | 20M |
| Long-Term Debt | 24M | 40M | 0 | 74K | 127K | 0 | N/A |
| Debt/Equity | -0.06 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | -69.4 | -14.3 | -12.8 | -15.1 | -1755.1 | -2536.4 | -2536.4 |
| Equity | -431M | 138M | 90M | 160M | 281M | 276M | 276M |
| Total Assets | 101M | 193M | 150M | 183M | 319M | 312M | 312M |
| Total Liabilities | 45M | 54M | 60M | 22M | 37M | 36M | 36M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -431M | -479M | -546M | -595M | -622M | -661M | -661M |
| Working Capital | 70M | 165M | 117M | 148M | 268M | 261M | 261M |
| Current Assets | 82M | 176M | 135M | 168M | 294M | 287M | 287M |
| Current Liabilities | 12M | 11M | 17M | 21M | 26M | 26M | 26M |
| Per Share Data | |||||||
| EPS | 0.15 | -3.57 | -2.41 | -1.41 | -0.71 | -0.95 | -0.95 |
| Owner EPS | -1.93 | -1.67 | -2.68 | -1.78 | -1.17 | -1.23 | -1.23 |
| Book Value | -19.19 | 4.09 | 3.25 | 4.65 | 7.27 | 6.73 | 6.73 |
| Cash Flow/Share | -1.57 | -1.32 | -2.12 | -1.21 | -0.44 | -0.38 | -0.87 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 22.4M | 33.8M | 27.7M | 34.5M | 38.7M | 41.0M | 41.0M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -7.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.5 | 3.6 | 8.8 | 4.7 | 1.6 | 1.1 |
| Price/Sales | N/A | N/A | 7.2 | 9.2 | 14.0 | 4.8 | 2.2 |
| FCF Yield | N/A | -13.4% | -18.8% | -3.3% | -1.7% | -4.3% | -6.5% |
| Market Cap | N/A | 349M | 325M | 1.4B | 1.3B | 448M | 298M |
| Avg. Price | N/A | 12.79 | 12.75 | 23.72 | 50.72 | 15.88 | 7.27 |
| Year-End Price | N/A | 10.33 | 11.74 | 40.78 | 34.22 | 10.93 | 7.27 |
RxSight, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 62.8%.
RxSight, Inc. (RXST) has a 5-year average return on invested capital (ROIC) of -31.2%. This is below average and may indicate limited pricing power.
RxSight, Inc. (RXST) has a market capitalization of $298M. It is classified as a small-cap stock.
RxSight, Inc. (RXST) does not currently pay a regular dividend.
RxSight, Inc. (RXST) operates in the Ophthalmic Goods industry, within the Healthcare sector.
RxSight, Inc. (RXST) reported annual revenue of $134 million in its most recent fiscal year, based on SEC EDGAR filings.
RxSight, Inc. (RXST) has a net profit margin of -29.0%. The company is currently unprofitable.
RxSight, Inc. (RXST) generated $-19 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
RxSight, Inc. (RXST) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
RxSight, Inc. (RXST) reported earnings per share (EPS) of $-0.95 in its most recent fiscal year.
RxSight, Inc. (RXST) has a return on equity (ROE) of -14.0%. A negative ROE may indicate losses or negative equity.
RxSight, Inc. (RXST) has a 5-year average gross margin of 62.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for RxSight, Inc. (RXST), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RxSight, Inc. (RXST) has a book value per share of $6.73, based on its most recent annual SEC filing.